J&J sign deal with Scottish firm AdoRx to develop novel lung cancer treatments

pharmafile | March 1, 2019 | News story | Medical Communications |  AdoRx, Cancer, Cancer Immunotherapy, J&J, JJ, immunology, oncology 

Edinburgh-based drug discovery firm AdoRx therapeutics has signed a deal with US healthcare conglomerate Johnson & Johnson to develop novel treatments for lung cancer.

The agreement allows J&J an exclusive option to research, develop and commercialise novel antagonists in AdoRx’s portfolio.

The financial terms of the agreement remain undisclosed.

Pete Finan, CEO of AdoRx, commented: “We are delighted to be teaming up with Johnson & Johnson and their Lung Cancer Initiative less than two years after the creation of AdoRx. The collaboration will facilitate the progression of AdoRx’s fit-for-purpose receptor antagonists into clinical development.”

Scottish firm AdoRx is developing treatments for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system.

AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels.

Louis Goss